About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

"The only way we can take care of our families is if we're around to do it," says Rodney Gillespie, US Head of Oncology at Novartis. For Rodney, cancer care isn’t just a professional responsibility—it ...

Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) 1,2 Significant unmet need remains in PNH, a chronic, rare and ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Job Title Sort ascending Business Location Site Date Posted Sr. Product Specialist (Hematology) Regular (Sales), Full time Innovative Medicines Türkiye Adana Feb 18, 2025 Senior UI & UX ...

Job Title Sort ascending Business Location Site Date Posted Sr. Product Specialist (Hematology) Regular (Sales), Full time Innovative Medicines Türkiye Adana Feb 18, 2025 Commercial Excellence Lead ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...